Form 4: Supernus Pharmaceuticals CEO Settles Performance Share Units, Adjusts Holdings
SEC Form 4 Filing
CEO Jack A. Khattar settles performance share units, resulting in adjustments to his direct and indirect holdings of Supernus Pharmaceuticals stock.
Summary
- On March 10, 2025, Supernus Pharmaceuticals CEO Jack A. Khattar settled 35,000 Performance Share Units, receiving 35,000 shares of common stock.
- The settlement of these units was a non-cash transaction, with the shares received at a price of $0.
- To cover tax obligations related to the vesting of these units, 16,805 shares of common stock were withheld by the company at a price of $32.06 per share.
- Following these transactions, Khattar directly holds 991,833 shares and indirectly holds 1,022,450 shares through the KBT Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, and does not inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of executive stock transactions, common for publicly traded companies. It provides transparency into the holdings and transactions of key company personnel.
Stakeholder Impact
- The transaction affects the total number of shares held by the CEO, which is of interest to shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/23/2023 | Reporting Person was awarded Performance Share Units |
| 06/12/2023 | Objectives for Performance Share Units were established |
| 03/10/2025 | Settlement of Performance Share Units and tax withholding |
| 03/11/2025 | Date of signature for the SEC filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.